Logo

InteRNA Partners with University of Bonn, UCB to Study microRNAs in Neurodegeneration

Jan 16, 2014
Premium

InteRNA Technologies last week announced that it is collaborating with the University of Bonn and Belgian biopharmaceutical firm UCB to identify and study microRNAs as therapeutic targets for neurodegenerative diseases.

According to the company, the alliance is part of the Neuroallianz Consortium, a German-funded academic-industry alliance focused on developing treatments for neurodegenerative conditions.

Specific terms of the partnership were not disclosed.

Filed under

Gene Editing, Gene Silencing, & CRISPR
RNAi
miRNA
InteRNA Technologies
Breaking News
The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.